ADVERTISEMENT

Scrip 100

Scrip 100: By The Numbers

Despite experiencing significant drops in pharmaceutical revenues in 2023, Pfizer and AbbVie maintained their top positions, ranking first and second respectively, in the latest Scrip 100.

The Scrip 100: Changes At The Top Of The Leaderboard

Pfizer continued its reign as the Scrip 100 leader for a third year, while Lilly and Novo climbed higher.

Scrip 100: By The Numbers

Pfizer dominated the Scrip 100 rankings of the top pharmaceutical companies in the world based on full year 2022 pharmaceutical sales, driven by its COVID-19 success.

COVID-19 Windfalls Carry Pharma Into Stormy Times: Key Takeaways From Scrip 100 And Outlook 2023

The past couple of years have generated important growth for the pharma industry thanks to its drugs and vaccines for COVID-19. But with the IRA, high inflation, rising interest rates and chilly public markets, biopharma faces challenges this year. Here, we summarize key messages from In Vivo’s Outlook 2023.

2017 Pharma Sales: A New Global Order

As the reality of annual results arrive, Scrip predicts how the top of the pharma league table is likely to change.

Infographic: Scrip 100 Numbers Crunched

This year's Scrip 100 collection is bigger than ever, encompassing 2016 full-year financial data from more than 650 biopharmaceutical companies.

Futurology: Are Mega Mergers A Thing Of The Past?

Bolt-ons or big-ticket buys? As another year passes without a big pharma mega merger despite industry giants sitting on large cash piles, we consider whether 2018 will bring major upheaval in the industry landscape, and where M&A will be most likely to take place.

Scrip 100 Analysis: Sales Up, Profits Down – But Is It Real?

Bellwethers tell you something, but to gauge the health of the pharmaceutical industry, you really need the Scrip 100. For FY 2016, it looks like drug sales are up again and profits are down. But is this what's actually going on?

Scrip 100 Analysis: Impairment, Youth Boost R&D Spending

Spending on R&D increased substantially in 2016; but the picture is complicated and more than half of the increase is due to accountancy updates following drug program failures, one large company's commitment to new projects, and young companies fuelled by generous financial markets.

EU Regulatory Review – What Pharma Should Remember From 2017

You could be forgiven for thinking that Brexit was the only story in town on the European regulatory front in 2017, but there were of course plenty of other important developments during the year.